---
title: "Janux Therapeutics, Inc. (JANX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/JANX.US.md"
symbol: "JANX.US"
name: "Janux Therapeutics, Inc."
industry: "生物技术"
---

# Janux Therapeutics, Inc. (JANX.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.januxrx.com](https://www.januxrx.com) |

## Company Profile

Janux Therapeutics, Inc.是一家临床阶段的生物制药公司，开发基于肿瘤激活 T 细胞连接器（TRACTr）和肿瘤激活免疫调节剂（TRACIr）平台技术的免疫疗法，以治疗癌症患者。其临床候选药物包括 JANX007，一种前列腺特异性膜抗原或 PSMA-TRACTr，目前正在进行针对转移性去势抵抗性前列腺癌及其他肿瘤血管的成人 1 期临床试验；以及 JANX008，一种表皮生长因子受体，目前正在进行针对多种实体癌症的 1 期临床试验，包括结直肠癌、头颈部鳞状细胞癌、非小细胞肺癌、肾细胞癌、小细胞肺癌、胰腺导管腺癌和三阴性乳腺癌。Janux Therapeutics, Inc.与...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: D (0.66)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 225 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -23.37% |  |
| Net Profit YoY | -68.32% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.83 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 807.18M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 10.00M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -12.48% | D |
| Profit Margin | -1018.95% | E |
| Gross Margin | -246.29% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -23.37% | E |
| Net Profit YoY | -68.32% | D |
| Total Assets YoY | 47.44% | A |
| Net Assets YoY | 48.84% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -9.81% | D |
| OCF YoY | -23.37% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.01 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 4.70% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Janux Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-12.48%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-1018.95%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-246.29%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-23.37%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-68.32%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "47.44%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "48.84%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-9.81%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-23.37%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "4.70%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.92 | 428/604 | - | - | - |
| PB | 0.83 | 69/604 | 1.72 | 1.47 | 0.97 |
| PS (TTM) | 80.72 | 244/604 | 3153.90 | 162.44 | 94.67 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **19**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 15 | 79% |
| Overweight | 3 | 16% |
| Hold | 1 | 5% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.08 |
| Highest Target | 150.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/JANX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/JANX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/JANX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
